Endoscopic surveillance recommendations for Barrett's Esophagus - AGA View

The American Gastroenterological Association (AGA) provides detailed recommendations for endoscopic surveillance in patients with Barrett’s Esophagus (BE). Below is a comprehensive summary of the AGA's guidelines based on the context provided:

1. Surveillance for Nondysplastic Barrett’s Esophagus (NDBE):

• Recommended Interval: Endoscopic surveillance is suggested every 3 years for patients with NDBE.
• Extended Interval: Surveillance may be extended to 5 years for patients at very low risk, such as those with short-segment BE (<3 cm).
• Discontinuation of Surveillance: Surveillance can be stopped in selected patients based on age and comorbidities. Factors to consider include:
• Life expectancy: Patients with limited life expectancy may not benefit from continued surveillance.
• Frailty: Frailty and other comorbid conditions should guide the decision to discontinue surveillance.

2. Surveillance for Ultra-Short Segment Barrett's Esophagus (<1 cm):

• No Surveillance Recommended: Endoscopic surveillance is not recommended for patients with ultra-short segment BE (less than 1 cm) with intestinal metaplasia.

3. Endoscopy Techniques for Surveillance:

• Preferred Approach: High-definition white light endoscopy (HD-WLE) combined with chromoendoscopy (CE) is preferred over HD-WLE alone.
• Recommendation Strength: Strong recommendation based on moderate-quality evidence.
• Type of Chromoendoscopy: Either virtual chromoendoscopy or dye-based chromoendoscopy is acceptable, depending on:
• Expertise of the endoscopist and
• Availability of equipment.
• Biopsy Protocol: Use chromoendoscopy-directed biopsies in addition to a structured biopsy protocol, such as the Seattle protocol:
• Seattle Protocol Guidelines:
• 4-quadrant biopsies every 2 cm for patients with no dysplasia.
• 4-quadrant biopsies every 1 cm for patients with a history of dysplasia.

4. Quality Standards for Barrett’s Exams:

• Barrett’s examinations must meet high-quality endoscopy standards, including:
• Optimal mucosal visualization.
• Adequate inspection time.
• Proper technique for mucosal evaluation.

5. Confirmation of Dysplasia Diagnosis:

• Any diagnosis of dysplasia must be confirmed by an expert pathologist.
• This is especially important for cases of indefinite for dysplasia (IND), low-grade dysplasia (LGD), and early neoplasia.

6. Management of New Diagnoses:

• For new diagnoses of Barrett’s Esophagus (BE), IND, or LGD:
• Repeat Endoscopy: Perform repeat endoscopy within 6 months.
• Medication: Patients should be on high-dose proton pump inhibitors (PPI) during this period to exclude prevalent high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).

7. Surveillance Intervals for Dysplasia:

• Low-Grade Dysplasia (LGD):
• If ablation therapy is not chosen, perform surveillance endoscopy every 6 months for 1 year, then annually thereafter.
• Indefinite for Dysplasia (IND):
• Annual surveillance endoscopy is recommended until the grade changes.
• No Endoscopic Eradication Therapy (EET): EET is not recommended for IND after expert review.

Key Points to Remember:

• Surveillance intervals depend on the presence and grade of dysplasia.
• High-quality endoscopic techniques and biopsy protocols are essential for accurate surveillance and diagnosis.
• Decisions regarding surveillance discontinuation should be individualized based on patient factors such as age, frailty, and life expectancy.

These recommendations aim to optimize the early detection and management of dysplasia and prevent progression to esophageal adenocarcinoma in patients with Barrett’s Esophagus.